Navigation Links
Protox Announces Publication in Journal of the National Cancer,Institute Supporting PRX302 as Treatment for Prostatic Diseases

ucted by Dr Arthur Frankel and his team at the Cancer Research Institute of Scott and White Memorial Hospital in collaboration with scientists at Protox and Johns Hopkins University. Key findings include: human prostate cancer cells are significantly more sensitive to PRX302 in the presence of active PSA; PRX302 was totally resistant to thrombin, matrix metalloprotease 7 (MMP-7), human kallikrein 1 (hk1) and human kallikrein 2 (hk2) activation; and among the normal cells tested, the PSA-producing prostate epithelial cells were the only normal cells that were highly sensitive to PRX302.

Both publications demonstrated that the PSA-activated strategy for PRX302 has a number of inherent advantages as a therapeutic strategy for locally recurrent prostate cancer and BPH.

About Protox

Protox Therapeutics is a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other proliferative diseases. The company is actively developing two distinct but complementary platforms, INxin(TM) and PORxin, and currently has three clinical programs in
development. A Phase IIa clinical trial into the use of PRX321 (INxin) for the treatment of primary brain cancer has been completed and the drug has received Fast Track Designation and Orphan Drug Status from the US FDA. In addition, a Phase I trial has been completed for PRX321 to treat patients with renal cell carcinoma and non-small cell lung cancer. Patient enrolment is underway for a Phase I clinical study into the use of PRX302 (PORxin) to treat localized prostate cancer. PRX302 has also been approved by Health Canada to commence a Phase I clinical study for the treatment of benign prostatic hyperplasia.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED THE CONTENT OF THIS RELEASE. THE TSX VENTURE EXCHANGE DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Certain st
'"/>




Page: 1 2 3

Related medicine technology :

1. Protox Announces Positive Clinical Data from Prostate Cancer Study
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:9/15/2014)... Quebec , Sept. 15, 2014  Valeant Pharmaceuticals ... announced that its wholly owned subsidiary, Valeant Pharmaceuticals International, ... principal amount of its 6.75% Senior Notes due 2017, ... October 15, 2014 and has mailed an irrevocable notice ... 15, 2014, a copy of the irrevocable notice of ...
(Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- MedicOne ... ambulance transport services, has been selected by Inc. ... companies in America. Photo - ... Inc. 500|5000 list identifies successful, privately-held companies with ... MedicOne Medical Response, one of only two ambulance ...
(Date:9/15/2014)... SINGAPORE , Sept. 15, 2014  Catalist-listed QT ... "the Group"), a developer and manufacturer of minimally invasive ... pleased to announce that the Group has enrolled the ... Germany . Multiple patients have already been ... , at Auckland City Hospital, in Auckland, ...
Breaking Medicine Technology:Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5
... (Nasdaq: ISIS ), the leader in antisense therapeutics, today ... Adams, 2009 Cardiovascular Conference on Tuesday, November 10, 2009, at ... , A live audio webcast of the presentation will be ... Web site, www.isispharm.com . A replay ...
... WASHINGTON, Nov. 2 The owner and operator of ... guilty to defrauding the Medicare program, announced Assistant Attorney ... Attorney Tim Johnson of the Southern District of Texas ... of Health & Human Services (HHS). , Noel Wayne ...
Cached Medicine Technology:Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 2Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 3
(Date:9/16/2014)... Dr. Eric Millstein of Beverly Hills is ... a specialty website devoted to the diagnosis and treatment ... lover and athlete, Dr. Millstein focuses on offering patients ... to maintain active, healthy lifestyles. , “We’re very excited ... specifically to ACL injuries and treatment,” says ...
(Date:9/16/2014)... 16, 2014 Lambda Solutions, a leader in ... is excited to welcome Stewart Rogers on board ... Executive at Lambda Solutions comments, “Product leadership will take Lambda ... to do so. Learning and talent management is at a ... help clinical learning and talent development in the past ten ...
(Date:9/16/2014)... Texas (PRWEB) September 16, 2014 Online ... be offering $0 shipping on all kettlebell purchases in ... easy for customers to get started with this effective ... the Crossfit movement. The online store carries a variety ... and free weekly workouts guides. , “We’ve ...
(Date:9/16/2014)... justthoughtyoushouldknow.org , popular current events, ... new site today. The new site is better ... information easier to find, ingest, and share. , ... easy-to-read pages the information that we believe any ... retired college professor and founder of the site. ...
(Date:9/16/2014)... 2014 Dakota Software , ... (EHS) and Sustainability management software, today announced that ... versatile software platform, MobileWorkflows, at their Annual Users ... MobileWorkflows allow for on-the-go access to Dakota’s enterprise-level ... Responsive Web Design, MobileWorkflows feature a streamlined user ...
Breaking Medicine News(10 mins):Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:Stewart Rogers Joins Lambda Solutions as Director of Product Management 2Health News:Stewart Rogers Joins Lambda Solutions as Director of Product Management 3Health News:Join the Kettlebell Movement - Kettlebell Kings Announces $0 Shipping on all Orders 2Health News:JustThoughtYouShouldKnow.org Debuts New Website 2Health News:Mobile EHS Compliance Tools the Focus of Dakota Software’s 2014 Users Conference 2
... In the report titled Millennium Ecosystem Assessment, scientists have said ... having a detrimental effect to human health and may cause ... malaria and cholera are threatening to cause a major outbreak ... beneficial factors of the eco system are being used in ...
... published in American Journal of Public Health, researchers had been ... causes of asthma in children by interventions due to health ... children in the age group of 4 to 12 yrs ... period of one year during which community health workers used ...
... US and Canadian scientists, consuming food with high glycemic index ... ,The study, which had spanned 16.6 years and observed ... that the risk is much significant for women who are ... often found in foods that have simple carbohydrates and sugars ...
... a data comprising of 5461 girls between 11 to 15 ... these girls more prone to stress fractures. ,The study ... physical activity, which often lasts for 16 or more hours ... of having a stress fracture than the girls doing physical ...
... market watchdog Food and Drug Administration had announced a series ... class of non-steroidal anti-inflammatory drugs that are sold with or ... of the drug Bextra (valdecoxib) from Pfizer, Inc. ... FDA had reports that the overall risk associated with the ...
... have completed the second phase of testing of the ... of cervical cancers and 90% of genital warts. ... for 36 months and regularly had gynecological examination, cervicovaginal ... serum antibodies to HPV. , ,The results showed ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: